India Pharma and Healthcare Sector Report 2023-2024

India's pharmaceuticals and healthcare sector is globally renowned. India has a reputation for being the “pharmacy of the world" thanks to its prodigious output of generic medicines and vaccines; notably, the Indian vaccine producer, Serum Institute of India, played a prominent role in manufacturing vaccines to combat the COVID-19 pandemic. Meanwhile, India's hospitals cater to a growing medical tourist base, thanks to their reputation for excellent yet affordable healthcare. Indian patients are increasingly able to access modern healthcare, thanks mainly to growing participation in Ayushman Bharat, the state-funded public health insurance programme. Despite these promising developments, India's pharmaceuticals and healthcare sector faces several pressing challenges. India has limited healthcare infrastructure thanks to decades of underfunding and a perennial exodus of skilled medical professionals to higher-paying countries. The Indian healthcare system also remains dependent on imported medical devices, pharmaceutical raw materials, and patented drugs due to limitations in domestic production capacity.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors